Superworth

Edwards Lifesciences price to free cash flow EW

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026
35.8×
10-year median
52.4×
Against its 10-year history
6th
percentile: 0 is its lowest day, 100 its highest
10-year range
32.6× to 205×
Peer median
20.2×

Edwards Lifesciences' price to free cash flow is 35.8× as of Oct 23, 2026.

That is below its ten-year median of 52.4×, lower than on 94% of days in the last ten years.

Over that time it ranged from 32.6× in Apr 2018 to 205× in Jun 2024.

The median for 7 medical device stocks of a similar size is 20.2×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far35.8×33.9×61.6×
202562.7×59.9×154×
202486.6×54.7×205×
202357.2×45.6×68.9×
202244.2×34.7×54.9×
202157.4×48.1×97.3×
202082.6×37.6×82.6×
201958.8×40.7×82.3×
201841.1×32.6×47.0×
201736.2×33.0×45.6×
201643.9×36.7×54.0×
201538.8×13.8×64.7×
201414.3×9.2×24.3×
201321.0×19.6×40.7×
201235.1×33.7×66.3×
201141.8×36.9×56.2×

Against its peers

Companies in Medical - Devices nearest Edwards Lifesciences' size, closest first, today.

CompanyPrice to free cash flow
EWEdwards Lifesciences35.8×
BSXBoston Scientific18.3×
GEHCGE HealthCare Technologies20.4×
DXCMDexCom20.9×
SYKStryker25.1×
MDTMedtronic19.9×
ZBHZimmer Biomet12.3×
ABTAbbott Laboratoriesn/m
Peer median20.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Edwards Lifesciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.